Your browser doesn't support javascript.
loading
Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk.
Sava, G P; Speedy, H E; Di Bernardo, M C; Dyer, M J S; Holroyd, A; Sunter, N J; Marr, H; Mansouri, L; Deaglio, S; Karabon, L; Frydecka, I; Jamroziak, K; Woszczyk, D; Juliusson, G; Smedby, K E; Jayne, S; Majid, A; Wang, Y; Dearden, C; Hall, A G; Mainou-Fowler, T; Jackson, G H; Summerfield, G; Harris, R J; Pettitt, A R; Allsup, D J; Bailey, J R; Pratt, G; Pepper, C; Fegan, C; Rosenquist, R; Catovsky, D; Allan, J M; Houlston, R S.
Afiliação
  • Sava GP; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK.
  • Speedy HE; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK.
  • Di Bernardo MC; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK.
  • Dyer MJ; The Ernest and Helen Scott Haematological Research Institute, Department of Biochemistry and Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK.
  • Holroyd A; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK.
  • Sunter NJ; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Marr H; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Mansouri L; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Deaglio S; Department of Medical Sciences and Human Genetics Foundation, University of Turin, Turin, Italy.
  • Karabon L; 1] Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland [2] Department and Clinic of Urology, Wroclaw Medical University, Wroclaw, Poland.
  • Frydecka I; Department of Experimental Therapy, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
  • Jamroziak K; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
  • Woszczyk D; Department of Haematology, State Hospital, Opole, Poland.
  • Juliusson G; Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Hematology and Transplantation, Lund University, Lund, Sweden.
  • Smedby KE; Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Jayne S; The Ernest and Helen Scott Haematological Research Institute, Department of Biochemistry and Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK.
  • Majid A; Medical Research Council Toxicology Unit, Leicester University, Leicester, UK.
  • Wang Y; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK.
  • Dearden C; Haemato-Oncology, Division of Pathology, The Institute of Cancer Research, Sutton, UK.
  • Hall AG; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Mainou-Fowler T; Haematological Sciences, Medical School, Newcastle University, Newcastle upon Tyne, UK.
  • Jackson GH; Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Summerfield G; Department of Haematology, Queen Elizabeth Hospital, Gateshead, Newcastle upon Tyne, UK.
  • Harris RJ; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Pettitt AR; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Allsup DJ; Department of Haematology, Hull Royal Infirmary, Hull, UK.
  • Bailey JR; Hull York Medical School and University of Hull, Hull, UK.
  • Pratt G; Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
  • Pepper C; Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
  • Fegan C; Cardiff and Vale National Health Service Trust, Heath Park, Cardiff, UK.
  • Rosenquist R; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
  • Catovsky D; Haemato-Oncology, Division of Pathology, The Institute of Cancer Research, Sutton, UK.
  • Allan JM; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Houlston RS; Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, UK.
Leukemia ; 29(3): 748-51, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25363670
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 12 / 2',5'-Oligoadenilato Sintetase / Íntrons / Leucemia Linfocítica Crônica de Células B / Polimorfismo de Nucleotídeo Único Tipo de estudo: Etiology_studies / Observational_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 12 / 2',5'-Oligoadenilato Sintetase / Íntrons / Leucemia Linfocítica Crônica de Células B / Polimorfismo de Nucleotídeo Único Tipo de estudo: Etiology_studies / Observational_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido